心血管疾病临床研究结局指标定义:EuroHeart项目
欧洲心脏病学会EuroHeart项目通过82名专家组成的五个工作组,采用系统综述和改良德尔菲法,为心血管疾病(通用)、急性冠脉综合征与经皮冠状动脉介入治疗、心房颤动、心力衰竭和经导管主动脉瓣植入术五个领域制定结局指标定义,共定义24个Level 1和48个Level 2结局指标。
要点
- 五个领域共定义24个Level 1(强制)和48个Level 2(可选)结局指标。
- Level 1指标分布:通用5个、ACS/PCI 8个、AF 2个、HF 5个、TAVI 4个。
- 指标定义可用于数据对齐,支持高质量观察性研究、随机试验、审计和质量改进。
核心结论
- 提出了国际来源且获认可的心血管常见疾病和干预的结局指标定义,可用于数据对齐以支持高质量研究和质量改进。
研究设计与样本
- EuroHeart项目由欧洲心脏病学会发起,采用EuroHeart数据标准开发方法,从82名专家组成的全球心血管结局联盟中成立五个工作组。
- 通过系统综述文献为改良德尔菲法提供信息,以达成最终变量集的共识。
主要发现
- 五个领域共定义24个Level 1(强制)和48个Level 2(可选)结局指标。
- Level 1指标数量:通用5个、ACS/PCI 8个、AF 2个、HF 5个、TAVI 4个。
- Level 2指标数量:通用18个、ACS-PCI 7个、AF 6个、HF 2个、TAVI 15个。
关键数值与推荐
- 每个变量由工作组提供定义,并根据临床重要性和可行性分类为Level 1(强制)或Level 2(可选)。
临床怎么用
- 这些定义可用于数据对齐,支持高质量观察性和随机临床研究、审计和质量改进,以惠及患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Standardized definitions for outcome measures in randomized clinical trials and observational studies are essential for robust and valid evaluation of medical products, interventions, care, and outcomes. The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology aimed to create international data standards for cardiovascular clinical study outcome measures. METHODS: The EuroHeart methods for data standard development were used. From a Global Cardiovascular Outcomes Consortium of 82 experts, five Working Groups were formed to identify and define key outcome measures for: cardiovascular disease (generic outcomes), acute coronary syndrome and percutaneous coronary intervention (ACS/PCI), atrial fibrillation (AF), heart failure (HF) and transcatheter aortic valve implantation (TAVI). A systematic review of the literature informed a modified Delphi method to reach consensus on a final set of variables. For each variable, the Working Group provided a definition and categorized the variable as mandatory (Level 1) or optional (Level 2) based on its clinical importance and feasibility. RESULTS: Across the five domains, 24 Level 1 (generic: 5, ACS/PCI: 8, AF: 2; HF: 5, TAVI: 4) and 48 Level 2 (generic: 18, ACS-PCI: 7, AF: 6, HF: 2, TAVI: 15) outcome measures were defined. CONCLUSIONS: Internationally derived and endorsed definitions for outcome measures for a range of common cardiovascular diseases and interventions are presented. These may be used for data alignment to enable high-quality observational and randomized clinical research, audit, and quality improvement for patient benefit.
引用
- Wilkinson C, Bhatty A, Batra G, et al. Definitions of clinical study outcome measures for cardiovascular diseases: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). Eur Heart J. 2025. PMID: 39545867. doi:10.1093/eurheartj/ehae724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。